Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Debiopharm Group Stories

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-04-02 04:21:07

LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ -- - Innovative partnership based on Evotec's Target X projects - Evotec and Debiopharm to share discovery and development efforts Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today a research collaboration and licensing deal with Debiopharm Group(TM), Lausanne, Switzerland. The objective of this collaboration is to identify and...

2014-03-06 04:23:27

LAUSANNE, Switzerland, March 6, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments, has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial...

2014-03-05 08:30:42

LAUSANNE, Switzerland and SEATTLE, March 5, 2014 /PRNewswire/ -- Immunexpress Group (Immunexpress) and Debiopharm Diagnostics SA (Debiopharm), today announced the securing of six million U.S. dollars from a financing round, led by Debiopharm. The funding will be used to advance development of the Immunexpress SeptiCyte(R) technology and bring one of the company's late-stage sepsis diagnostic products through to market. Immunexpress is a molecular diagnostic company...

2014-02-11 08:33:36

LAUSANNE, Switzerland, February 11, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, and Affinium Pharmaceuticals (Affinium), a Canadian company focusing on the development of a platform of novel, targeted narrow-spectrum antibacterial therapeutics, today announced the acquisition by Debiopharm of Affinium's clinical and...

2014-01-13 12:28:06

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg. Debiopharm is investigating the efficacy and safety of...

2014-01-08 04:21:06

LAUSANNE, Switzerland, January 8, 2014 /PRNewswire/ -- Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the successful achievement of a second development milestone on Spinomix' two proprietary...

2013-10-24 12:26:35

GENEVA and LAUSANNE, Switzerland, October 24, 2013 /PRNewswire/ -- Atheris Laboratories, a world leading company in venom-based drug discovery and lead optimization, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology along with companion diagnostics, today announced the signature of a collaboration agreement regarding the Atheris "Reverse-Discovery"(TM) lead...

2013-10-22 08:33:17

Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus LAUSANNE, Switzerland and LEXINGTON, Massachusetts, October 22, 2013 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a...

2013-10-07 04:21:07

SINGAPORE and LAUSANNE, Switzerland, October 7, 2013 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today...